SNY vs UTHR
Sanofi vs United Therapeutics — AI-powered side-by-side comparison
SNY
Sanofi
62
Insufficient Data
VS
UTHR
United Therapeutics
72
Buy
| Metric | SNY | UTHR |
|---|
| AI Score |
62
|
72
|
| Price |
$43.56
|
$514.89
|
| P/E Ratio |
23.06×
|
17.05×
|
| ROE |
10.9%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
72.8%
|
86.1%
|
| Debt / Equity |
0.34×
|
0.00×
|
| Dividend Yield |
5.5%
|
0.0%
|
| RSI (14) |
53.1
|
52.2
|
| Beta |
0.278
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for SNY versus UTHR.
UTHR leads by 10 points.
UTHR scores 72/100 (Buy) versus SNY at 62/100 (Insufficient Data).
SNY Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Trend and market structure agree -- coherent bearish picture — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.